In a cost-effectiveness analysis conducted in 2003, three primary therapy protocols for moderate to severe AD were compared: high-potency topical corticosteroids (HPTCs) limited to 2-week intervals, ...

More patients with atopic dermatitis achieved mild disease severity by 1 month of treatment with adjuvant dupilumab and tacrolimus vs dupilumab alone. A greater proportion of patients with atopic ...

From the 25 subjects recruited, two refused to participate after reading the informed consent form. The others were assigned to the study groups, including 12 to the experimental group and 11 to the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Pimecrolimus, ...

Pimecrolimus and tacrolimus, 2 topical calcineurin inhibitors for the treatment of atopic dermatitis (AD), were not shown to increase the risk of cancer based on moderate-certainty evidence from a ...

The calcineurin inhibitor tacrolimus is an immunosuppressive drug frequently used to prevent transplant rejection in solid organ transplant patients. Tacrolimus acts by suppressing T-cell activity ...

Topical tacrolimus and pimecrolimus are not recommended for the treatment of mild atopic eczema or as first-line treatments for atopic eczema of any severity. Topical tacrolimus is recommended, within ...

Please provide your email address to receive an email when new articles are posted on . Pimecrolimus improved six of seven assessed outcomes. Upadacitinib was among the most effective but also most ...

Atopic dermatitis is one of the most common chronic inflammatory skin diseases worldwide and is also the most common form of eczema. Although infants and children are most often affected, adults can ...

Pimecrolimus, a calcineurin inhibitor immunosuppressant, was found to provide the most improvement with regard to gaining AD control. Pimecrolimus, tacrolimus, and moderate potency topical ...